CytRx con­cedes that its on­ly drug flunked a PhI­II sar­co­ma test, rout­ing shares

Three years af­ter one of its drugs had to be scrapped fol­low­ing a failed study, CytRx was forced to con­cede that its Phase III study of its lead drug al­dox­oru­bicin flopped against treat­ment re­sis­tant soft tis­sue sar­co­mas.

The com­pa­ny tried to put the most pos­i­tive spin on it, say­ing that the re­sults had been con­found­ed by an in­ter­rup­tion due to a tem­po­rary par­tial clin­i­cal hold in 2014. But the pro­gres­sion-free sur­vival rate for the drug came in at 4.17 months, hard­ly dis­tin­guish­able from the 4.04 months tracked for in­ves­ti­ga­tors’ choice among stan­dard treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER